<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Vicore Pharma Holding Ab — News on 6ix</title>
    <link>https://6ix.com/company/vicore-pharma-holding-ab</link>
    <description>Latest news and press releases for Vicore Pharma Holding Ab on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 06 May 2026 14:45:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/vicore-pharma-holding-ab" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d573b3beedb30cb6f865b8.webp</url>
      <title>Vicore Pharma Holding Ab</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab</link>
    </image>
    <item>
      <title>Announcement from the Annual General Meeting of Vicore Pharma Holding AB (publ)</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab/news/announcement-from-the-annual-general-meeting-of-vicore-pharma-holding-ab-publ-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vicore-pharma-holding-ab/news/announcement-from-the-annual-general-meeting-of-vicore-pharma-holding-ab-publ-1</guid>
      <pubDate>Wed, 06 May 2026 14:45:00 GMT</pubDate>
      <description>STOCKHOLM, SE / ACCESS Newswire / May 6, 2026 /Today on 6 May 2026, the Annual General Meeting (the &quot;AGM&quot;) of Vicore Pharma Holding AB (publ) (&quot;Vicore Pharma&quot; or the &quot;Company&quot;)(STO:VICO) was held, whereby the shareholders passed the following resolutions. ...</description>
    </item>
    <item>
      <title>Vicore Pharma Announces Presentations at the 2026 American Thoracic Society International Conference</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-pharma-announces-presentations-at-the-2026-american-thoracic-society-international-conference-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-pharma-announces-presentations-at-the-2026-american-thoracic-society-international-conference-1</guid>
      <pubDate>Wed, 29 Apr 2026 06:20:00 GMT</pubDate>
      <description>STOCKHOLM, SE / ACCESS Newswire / April 29, 2026 /Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today ...</description>
    </item>
    <item>
      <title>Vicore Pharma Completes Enrollment in the Phase 2b ASPIRE Trial of Buloxibutid in Idiopathic Pulmonary Fibrosis</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-pharma-completes-enrollment-in-the-phase-2b-aspire-trial-of-buloxibutid-in-idiopathic-pulmonary-fibrosis-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-pharma-completes-enrollment-in-the-phase-2b-aspire-trial-of-buloxibutid-in-idiopathic-pulmonary-fibrosis-1</guid>
      <pubDate>Wed, 22 Apr 2026 06:20:00 GMT</pubDate>
      <description>The randomized Phase 2b ASPIRE trial successfully completed planned enrollment of over 360 patients, reflecting strong execution and robust site engagement ASPIRE is designed to assess the effect of buloxibutid on forced vital capacity (FVC) over ...</description>
    </item>
    <item>
      <title>Vicore Publishes the Annual Report for 2025</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-publishes-the-annual-report-for-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-publishes-the-annual-report-for-2025-1</guid>
      <pubDate>Thu, 26 Mar 2026 07:25:00 GMT</pubDate>
      <description>STOCKHOLM, SE / ACCESS Newswire / March 26, 2026 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced the publication of the Annual Report for the ...</description>
    </item>
    <item>
      <title>Vicore Pharma to Present at Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-pharma-to-present-at-upcoming-investor-conferences-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-pharma-to-present-at-upcoming-investor-conferences-1</guid>
      <pubDate>Mon, 09 Mar 2026 07:15:00 GMT</pubDate>
      <description>STOCKHOLM, SE / ACCESS Newswire / March 9, 2026 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the following ...</description>
    </item>
    <item>
      <title>Vicore Pharma Elevates Leadership Team Ahead of Key Clinical and Corporate Milestones</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-pharma-elevates-leadership-team-ahead-of-key-clinical-and-corporate-milestones-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-pharma-elevates-leadership-team-ahead-of-key-clinical-and-corporate-milestones-1</guid>
      <pubDate>Thu, 05 Mar 2026 07:20:00 GMT</pubDate>
      <description>STOCKHOLM, SE / ACCESS Newswire / March 5, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced the promotion of three internal ...</description>
    </item>
    <item>
      <title>Year-End Report 2025</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab/news/year-end-report-2025-2</link>
      <guid isPermaLink="true">https://6ix.com/company/vicore-pharma-holding-ab/news/year-end-report-2025-2</guid>
      <pubDate>Fri, 27 Feb 2026 07:20:00 GMT</pubDate>
      <description>STOCKHOLM, SE / ACCESS Newswire / February 27, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today published the year-end report for 2025. ...</description>
    </item>
    <item>
      <title>Vicore Pharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-pharma-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-pharma-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference-1</guid>
      <pubDate>Wed, 18 Feb 2026 07:15:00 GMT</pubDate>
      <description>STOCKHOLM, SE / ACCESS Newswire / February 18, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company ...</description>
    </item>
    <item>
      <title>Vicore Pharma to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-pharma-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-pharma-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-1</guid>
      <pubDate>Wed, 07 Jan 2026 07:15:00 GMT</pubDate>
      <description>STOCKHOLM, SE / ACCESS Newswire / January 7, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will ...</description>
    </item>
    <item>
      <title>Vicore Pharma To Move To The Nasdaq Stockholm Mid Cap Segment</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-pharma-to-move-to-the-nasdaq-stockholm-mid-cap-segment-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-pharma-to-move-to-the-nasdaq-stockholm-mid-cap-segment-1</guid>
      <pubDate>Fri, 19 Dec 2025 07:15:00 GMT</pubDate>
      <description>STOCKHOLM, SE / ACCESS Newswire / December 19, 2025 / Vicore Pharma Holding AB (publ) (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs) today announced that Nasdaq has completed its annual ...</description>
    </item>
    <item>
      <title>Vicore to Present at the Oppenheimer Movers in Rare Disease Summit</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-to-present-at-the-oppenheimer-movers-in-rare-disease-summit-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-to-present-at-the-oppenheimer-movers-in-rare-disease-summit-1</guid>
      <pubDate>Fri, 05 Dec 2025 07:15:00 GMT</pubDate>
      <description>STOCKHOLM, SE / ACCESS Newswire / December 5, 2025 / Vicore Pharma Holding AB (publ) (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the Oppenheimer ...</description>
    </item>
    <item>
      <title>Increase in Number of Shares and Votes in Vicore Pharma</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab/news/increase-in-number-of-shares-and-votes-in-vicore-pharma-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vicore-pharma-holding-ab/news/increase-in-number-of-shares-and-votes-in-vicore-pharma-1</guid>
      <pubDate>Fri, 28 Nov 2025 08:30:00 GMT</pubDate>
      <description>STOCKHOLM, SE / ACCESS Newswire / November 28, 2025 / Vicore Pharma Holding AB (publ) (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs) today announced that the number of shares and votes ...</description>
    </item>
    <item>
      <title>Vicore to Present at the DNB Carnegie Nordic Healthcare Conference</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-to-present-at-the-dnb-carnegie-nordic-healthcare-conference-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-to-present-at-the-dnb-carnegie-nordic-healthcare-conference-1</guid>
      <pubDate>Thu, 20 Nov 2025 07:20:00 GMT</pubDate>
      <description>STOCKHOLM, SE / ACCESS Newswire / November 20, 2025 / Vicore Pharma Holding AB (publ) (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the DNB Carnegie ...</description>
    </item>
    <item>
      <title>Vicore to Present at The Jefferies Global Healthcare Conference in London</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-to-present-at-the-jefferies-global-healthcare-conference-in-london-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-to-present-at-the-jefferies-global-healthcare-conference-in-london-1</guid>
      <pubDate>Mon, 17 Nov 2025 07:20:00 GMT</pubDate>
      <description>STOCKHOLM, SE / ACCESS Newswire / November 17, 2025 / Vicore Pharma Holding AB (publ) (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the Jefferies Global ...</description>
    </item>
    <item>
      <title>Vicore to Present at Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-to-present-at-upcoming-investor-conferences-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-to-present-at-upcoming-investor-conferences-1</guid>
      <pubDate>Wed, 05 Nov 2025 07:50:00 GMT</pubDate>
      <description>STOCKHOLM, SE / ACCESS Newswire / November 5, 2025 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following conferences: ...</description>
    </item>
    <item>
      <title>Interim Report July - September 2025</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab/news/interim-report-july-september-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vicore-pharma-holding-ab/news/interim-report-july-september-2025-1</guid>
      <pubDate>Wed, 05 Nov 2025 07:15:00 GMT</pubDate>
      <description>STOCKHOLM, SE / ACCESS Newswire / November 5, 2025 / Vicore Pharma Holding (STO:VICO) - Stockholm, November 5, 2025 - Vicore Pharma Holding AB (STO:VICO) unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), ...</description>
    </item>
    <item>
      <title>Vicore Announces The Nomination Committee For The 2026 Annual General Meeting</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-announces-the-nomination-committee-for-the-2026-annual-general-meeting-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-announces-the-nomination-committee-for-the-2026-annual-general-meeting-1</guid>
      <pubDate>Mon, 03 Nov 2025 09:20:00 GMT</pubDate>
      <description>STOCKHOLM, SE / ACCESS Newswire / November 3, 2025 / Vicore Pharma Holding (STO:VICO) - Stockholm, November 3, 2025 - Vicore Pharma Holding AB (publ)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists ...</description>
    </item>
    <item>
      <title>Buloxibutid Receives Orphan Drug Designation in Japan for the Treatment of Idiopathic Pulmonary Fibrosis</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab/news/buloxibutid-receives-orphan-drug-designation-in-japan-for-the-treatment-of-idiopathic-pulmonary-fibrosis-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vicore-pharma-holding-ab/news/buloxibutid-receives-orphan-drug-designation-in-japan-for-the-treatment-of-idiopathic-pulmonary-fibrosis-1</guid>
      <pubDate>Tue, 30 Sep 2025 06:50:00 GMT</pubDate>
      <description>STOCKHOLM, SE / ACCESS Newswire / September 30, 2025 /Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that Japan&apos;s Ministry of Health, Labor ...</description>
    </item>
    <item>
      <title>Vicore Announces Presentations at the European Respiratory Society Congress 2025</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-announces-presentations-at-the-european-respiratory-society-congress-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-announces-presentations-at-the-european-respiratory-society-congress-2025-1</guid>
      <pubDate>Tue, 23 Sep 2025 06:15:00 GMT</pubDate>
      <description>STOCKHOLM, SE / ACCESS Newswire / September 23, 2025 /Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will present at the European ...</description>
    </item>
    <item>
      <title>Vicore to Present at Pareto Securities&apos; 16th Annual Healthcare Conference</title>
      <link>https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-to-present-at-pareto-securities-16th-annual-healthcare-conference-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vicore-pharma-holding-ab/news/vicore-to-present-at-pareto-securities-16th-annual-healthcare-conference-1</guid>
      <pubDate>Mon, 15 Sep 2025 06:20:00 GMT</pubDate>
      <description>STOCKHOLM, SE / ACCESS Newswire / September 15, 2025 /Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation at Pareto Securities&apos; 16th ...</description>
    </item>
  </channel>
</rss>